Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sézary syndrome

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome

2003 • 390 citations

Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders

2006 • 263 citations

Opportunistic Infections in 547 Organ Transplant Recipients Receiving Alemtuzumab, a Humanized Monoclonal CD-52 Antibody

2006 • 261 citations

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

2003 • 230 citations

Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*

2005 • 181 citations

Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath)

2005 • 125 citations

Updated Guidelines on the Management of Cytomegalovirus Reactivation in Patients with Chronic Lymphocytic Leukemia Treated with Alemtuzumab

2006 • 95 citations

Routine clinical use of alemtuzumab in patients with heavily pretreated B‐cell chronic lymphocytic leukemia

2006 • 44 citations

Fatal Adenovirus Infection During Alemtuzumab (Anti-CD52 Monoclonal Antibody) Treatment of a Patient with Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia

2002 • 35 citations

EBV negative Richter's syndrome from a coexistent clone after salvage treatment with alemtuzumab in a CLL patient

2006 • 15 citations